Hematologic Malignancy
Angiocentric Immunoproliferative Lesion
CI-CAN-00000451AILExplore in graph →
HematologicNon-malignant2 active trials
- NCIt
- C40970
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000451AILExplore in graph →
Clinical trials
83 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2016source: clinicaltrials